[Durgical](https://durgical.com/en/) › [DurgiPedia](https://durgical.com/en/durgipedia/) › [Haematology](https://durgical.com/en/haematology/) › [Haemostasis, bleeding and thrombosis](https://durgical.com/en/haematology/areas/haemostasis/) › Haemophilia care: prophylaxis, inhibitors, non-factor therapy, joints

# Haemophilia care: prophylaxis, inhibitors, non-factor therapy, joints

- Treatment and support

Severe haemophilia used to mean crippled joints by early adulthood. Regular prevention, started early, now lets most children grow up with healthy joints.

Updated Nov 15, 2026

## Key points

- Severe haemophilia: prophylaxis from early childhood prevents arthropathy.
- Inhibitor = alloantibody; suspect when factor stops working; treat bleeds with bypassing agents.
- [Emicizumab](https://durgical.com/en/pharmacology/emicizumab/) mimics factor [VIII](https://durgical.com/en/anatomy/vestibulocochlear-nerve/) (links IXa and X): haemophilia A only, prophylaxis only.
- Emicizumab makes aPTT useless; use chromogenic bovine factor VIII assays.
- Factor before imaging in head injury.
- Target joint: three or more bleeds in one joint within six months.

On this page

- The basics Key points
- What it is
- How to think about it
- What to know
- How it is done (and why)
- Common traps
- Elsewhere in DurgiPedia

- Safety Risks and precautions
- Monitoring and next step

- Study Test yourself

- Connections Connections

## What it is

Modern haemophilia care aims to stop bleeds before they happen rather than treat them afterwards. In severe disease this means prophylaxis: regular replacement of the missing factor (VIII or IX), or, in haemophilia A, a non-factor drug that does factor VIII's job. Care is planned by a comprehensive haemophilia team (haematologist, nurse, physiotherapist, dentist, social support). The two big threats are joint damage from repeated bleeds and inhibitors, [antibodies](https://durgical.com/en/biochemistry/enzymes/immunoglobulins/) that make replacement factor useless.

## How to think about it

Think of the clotting system as a bridge with one plank missing. Factor replacement lays a new plank, but it wears out within days and must be relaid on schedule; if the body attacks the new plank (an inhibitor), you build a detour around the gap (bypassing agents). Non-factor drugs change the bridge itself: one holds the two banks together where the plank was, others loosen the brakes so the rest of the bridge carries more traffic.

## What to know

- Prophylaxis in severe haemophilia keeps the factor level from ever falling to the point where joints bleed by themselves; it is started in early childhood, ideally before joint damage begins.
- On-demand treatment (factor only when a bleed happens) prevents death from bleeding but not progressive joint damage.
- Extended half-life factor concentrates last longer in the blood, so fewer infusions are needed for the same protection.
- Inhibitors are alloantibodies against infused factor; they are commonest in severe haemophilia A and usually appear in the first months of treatment.
- Bleeds in a patient with an inhibitor are treated with bypassing agents (recombinant activated factor VII or activated prothrombin complex concentrate), which make thrombin without needing factor VIII or IX.
- Emicizumab is a bispecific antibody that links factor IXa and factor X, copying the bridging role of factor VIII; it is given under the skin as prophylaxis for haemophilia A with or without inhibitors.
- Newer agents rebalance clotting by lowering natural anticoagulants (antithrombin or tissue factor pathway inhibitor), and [gene therapy](https://durgical.com/en/biochemistry/topics/gene-therapy/) that lets the [liver](https://durgical.com/en/anatomy/liver/) make the factor is available in some countries.

## How it is done (and why)

- Confirm the type (A or B) and severity from the factor level; severe disease is the main candidate for prophylaxis.
- Choose the prophylaxis: factor replacement (standard or extended half-life) or, in haemophilia A, a non-factor agent.
- Teach home treatment: families and patients learn to infuse or inject so a bleed is treated within minutes, not hours.
- Test for an inhibitor early in treatment, before surgery and whenever a bleed responds poorly to the usual factor.
- If an inhibitor appears: treat bleeds with bypassing agents and consider immune tolerance induction, frequent regular factor to retrain the immune system.
- Protect the joints: treat every joint bleed at once, then physiotherapy; a target joint gets intensified prophylaxis.
- Plan dentistry and surgery with the haemophilia team: factor cover, [tranexamic acid](https://durgical.com/en/pharmacology/tranexamic-acid/) for mouth bleeding, and the right laboratory test for the drug in use.

## Risks and precautions

- A suspected bleed is treated first and investigated second: give factor (or the agreed agent) before imaging in head injury, deep muscle bleeds or a painful swollen joint.
- Each joint bleed leaves [iron](https://durgical.com/en/biochemistry/topics/iron/) in the synovium, which inflames it and makes it bleed again; three or more spontaneous bleeds in one joint within six months define a target joint.
- Repeated bleeding ends in [haemophilic arthropathy](https://durgical.com/en/conditions/arthritis-as-a-clue-to-systemic-disease/): chronic synovitis, cartilage loss, deformity and pain, most often in knees, elbows and ankles.
- Iliopsoas bleeds can mimic appendicitis or hip disease and may compress the [femoral nerve](https://durgical.com/en/anatomy/femoral-nerve/); forearm and calf bleeds can cause [compartment syndrome](https://durgical.com/en/conditions/acute-compartment-syndrome/).
- Avoid intramuscular injections, [aspirin](https://durgical.com/en/pharmacology/acetylsalicylic-acid/) and [NSAIDs](https://durgical.com/en/pharmacology/classes/nonsteroidal-anti-inflammatory-drugs/); vaccines are given under the skin with local pressure.
- In Colombia haemophilia care is organised through specialised centres and followed as a high-cost disease (Cuenta de Alto Costo).

## Monitoring and next step

- Factor VIII or IX level at diagnosis sets the severity; carriers have their own level measured before delivery or surgery.
- Inhibitor screen (Bethesda assay) early in treatment, before surgery and whenever treatment seems to fail; the titre guides the choice between factor and bypassing agents.
- On emicizumab, aPTT-based tests are falsely normal: measure factor VIII with a chromogenic assay using bovine reagents, as the laboratory advises.
- Joint assessment by examination and, where available, point-of-care ultrasound to tell a bleed from synovitis.
- Screen for infections acquired from old plasma products (HIV, hepatitis B and C) in older patients.

## Common traps

- **Waiting for imaging before giving factor in a head injury**: in severe haemophilia the factor goes first and the CT second
- **Treating a breakthrough bleed on emicizumab with activated prothrombin complex concentrate in the usual way**: the combination has caused thrombotic microangiopathy and thrombosis, so the team's specific plan is followed
- **Trusting a normal aPTT in a patient on emicizumab**: the drug shortens the aPTT regardless of the bleeding risk, so it cannot be used to judge protection
- **Thinking a bleed that does not stop simply needs more of the same factor**: a poor response is the classic sign of a new inhibitor and needs testing
- **Assuming emicizumab works in haemophilia B**: it replaces the role of factor VIII only

## Test yourself

Think of the answer, then tap the question to see it.

## A 2-year-old boy with severe haemophilia A falls and hits his head; he seems well. What should be done first, and why?

Give factor VIII (or the agreed agent) at once, then image the head: intracranial bleeding can be silent at first, and waiting for the scan loses time that decides the outcome.

## A 9-month-old with severe haemophilia A on factor prophylaxis now bleeds despite his usual infusions. What is the likely cause and the next test?

A new inhibitor (alloantibody against factor VIII), which usually appears early in treatment; measure it with a Bethesda assay.

## Why does emicizumab work even when a patient has a factor VIII inhibitor?

It is not factor VIII: it is an antibody that links factor IXa and factor X directly, so the inhibitor has nothing to attack.

## Why does on-demand treatment alone fail to protect the joints in severe haemophilia?

Many joint bleeds start silently, and each one leaves iron that inflames the synovium; only keeping the factor up continuously prevents the cycle of bleeding and synovitis.

[Add to my cards (4)](https://durgical.app/estudiar/?add=/en/haematology/haemophilia-care-prophylaxis-inhibitors-non-factor-therapy-joints/)

## Elsewhere in DurgiPedia

- [Haemophilia A and B](https://durgical.com/en/general-pathology/haemophilia-a-and-b/)
- [The coagulation cascade](https://durgical.com/en/physiology/the-coagulation-cascade/)
- [Synovial joints: capsule, synovial membrane and articular cartilage](https://durgical.com/en/histology/synovial-joints-capsule-synovial-membrane-and-articular-cartilage/)
- [Bleeding and clotting disorders: haemophilia, ITP and watching for DIC](https://durgical.com/en/nursing/bleeding-and-clotting-disorders-haemophilia-itp-and-watching-for-dic/)
- [Bleeding after a tooth extraction](https://durgical.com/en/dentistry/bleeding-after-a-tooth-extraction/)

## Connections

## Related 5

- [Von Willebrand disease versus haemophilia](https://durgical.com/en/haematology/von-willebrand-disease-versus-haemophilia/)
- [Clotting tests: which one answers which question](https://durgical.com/en/haematology/clotting-tests-which-one-answers-which-question/)
- [Acquired haemophilia and acquired von Willebrand syndrome](https://durgical.com/en/haematology/acquired-haemophilia-and-acquired-von-willebrand-syndrome/)
- [The bleeding patient: plug or glue, then the PT and aPTT grid](https://durgical.com/en/haematology/the-bleeding-patient-plug-or-glue-then-the-pt-and-aptt-grid/)
- [Before surgery: the bleeding history and when clotting tests help](https://durgical.com/en/haematology/before-surgery-the-bleeding-history-and-when-clotting-tests-help/)

## Related conditions 2

- [Haemophilia A and B](https://durgical.com/en/conditions/haemophilia-a-and-b/)
- [Von Willebrand disease](https://durgical.com/en/conditions/von-willebrand-disease/)

[← All of haematology](https://durgical.com/en/haematology/)

Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.

Sources: [Treatment of Hemophilia | Hemophilia | CDC](https://www.cdc.gov/hemophilia/treatment/index.html) (Centers for Disease Control and Prevention, 2026); [Hemophilia A](https://www.ncbi.nlm.nih.gov/books/NBK470265/) (StatPearls (NCBI Bookshelf), 2026); [Emicizumab](https://www.ncbi.nlm.nih.gov/books/NBK559180/) (StatPearls (NCBI Bookshelf), 2023).

## **Spotted a mistake?** We are always improving for the community. Tell us what is wrong and our team will review it. Report a mistake

Representative model, for educational purposes only.

---
Source: https://durgical.com/en/haematology/haemophilia-care-prophylaxis-inhibitors-non-factor-therapy-joints/
License: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Cite as: DurgiPedia (durgical.com), https://durgical.com/en/haematology/haemophilia-care-prophylaxis-inhibitors-non-factor-therapy-joints/
